CAMP4 Therapeutics remains in a high-risk, early-stage development phase where the proprietary regRNA platform serves as the primary value driver despite the absence of recurring commercial revenue. While the company has successfully bolstered its liquidity to...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.58-174.3% vs -$0.21 | $2M+9.8% vs $2M |
Q2 2026 May 7, 2026 | -$0.32-52.4% vs -$0.21 | $1M+15.7% vs $1M |
Q2 2026 Mar 5, 2026 | -$0.87-180.6% vs -$0.31 | $300,000-36.9% vs $475,200 |
Q4 2025 Nov 6, 2025 | -$0.55-17.0% vs -$0.47 | $795,000+83.5% vs $433,333 |
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4's executive leadership team and participation from patient advocates and a leading KOL. To register, click here.
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:
Vancouver, British Columbia – TheNewswire - August 31, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (“ Canadian GoldCamps ” or the “ Company ”) announces that, further to its news release dated August 18, 2026, it has completed the acquisition of an initial 85% undivided interest in the Stealthwall West Project (the “Project”), located in the Caniapiscau district of northeastern Québec. The acquisition was completed pursuant to the definitive property acquisition and option agreement dated August 17, 2026 (the “Agreement”) with the arm's length vendors of the Project (the “Vendors”). Pursuant to the Agreement, the Company acquired an initial 85% undivided interest in the Stealthwall West Project (the “Project”), located in the Caniapiscau district of northeastern Québec (the “Transaction”). The Project comprises 50 contiguous mining claims, CDC 2865583 through CDC 2865632, on NTS map sheet 23C10 in the unorganized territory of Rivière-Mouchalagane, MRC de Caniapiscau, Côte-Nord, Québec. The claims cover an aggregate area of approximately 2,612.5 hectares.
Benchmark CAMP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CAMP4 Therapeutics Corporation (CAMP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.72 | $79.01M | -1.40 | 436.5% | -2298.54% | -145.07% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $341.75 | $10.07B | 49.96 | 33.94% | 54.82% | 19.34% | — |
CAMP4 Therapeutics Corporation (CAMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CAMP4 Therapeutics Corporation (CAMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 4, 2026·SEC
Jul 27, 2026·SEC
Get notified when CAMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CAMP4 Therapeutics Corporation (CAMP) stock FAQ — growth, dividends, profitability & financials explained
CAMP4 Therapeutics Corporation (CAMP) reported $4.2M in revenue for fiscal year 2025. This represents a 91% decrease from $49.3M in 1996.
CAMP4 Therapeutics Corporation (CAMP) grew revenue by 436.5% over the past year. This is strong growth.
CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $107.2M for fiscal year 2025.
CAMP4 Therapeutics Corporation (CAMP) has a return on equity (ROE) of -145.1%. Negative ROE indicates the company is unprofitable.
CAMP4 Therapeutics Corporation (CAMP) had negative free cash flow of $28.7M in fiscal year 2025, likely due to heavy capital investments.
